Active ingredientAvacopanCat. No. P-A217-001CAS 1346623-17-3Family · Pharmaceutical analytical standards
Avacopan
An oral antagonist of the receptor for complement fragment C5a, approved in 2021 in Japan and the United States for ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis); in the European Union, where it was authorised in 2022, the authorisation was revoked in 2026. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was the first oral inhibitor of the complement C5a receptor approved in the United States, and both the FDA and the EMA considered it a first-in-class medicine.
Go to the active ingredient →Active ingredientAvacopanCat. No. P-A217-001CAS 1346623-17-3
MetaboliteAvacopan Metabolite 1Cat. No. P-A217-002CAS 1346623-14-0
Isotopically labelledAvacopan-d4Cat. No. P-A217-003CAS 2316781-85-6
NitrosamineN-Nitroso AvacopanCat. No. P-A217-004
ImpurityAvacopan Impurity 1Cat. No. P-A217-005
Impurityent-AvacopanCat. No. P-A217-006No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.